› Forums › General Melanoma Community › For Jimmy B
- This topic has 3 replies, 1 voice, and was last updated 14 years, 2 months ago by
jim Breitfeller.
- Post
-
- November 8, 2011 at 7:50 pm
Hi Jimmy,
First of all, my first scan after Yervoy treatments showed 50% regression in my lung mets – including some that are gone. 2 grea just a tad, but we'll see how those look on November 30th when I get my next scan. It could very well be inflammation.
Hi Jimmy,
First of all, my first scan after Yervoy treatments showed 50% regression in my lung mets – including some that are gone. 2 grea just a tad, but we'll see how those look on November 30th when I get my next scan. It could very well be inflammation.
Bad news – I got 2 brain mets while on ipi or before (small). My last brain MRI was July 28th, so I have no idea how long these have been sitting there. A couple of Dr's in the U.S. have claimed that people who have success on ipi may get brain tumours which get removed and not come back for quite some time. Do you know anything about this? I have 1 brain met that has bled and is now absorbing – we can't even see the tumour at all on an MRI and my oncologist is starting to wonder if it may be ipi that has done this. Does ipi cause bleeding in tumours?
Anyway, I'm really hoping my lymphocytes are in my brain now trying to keep anything more from growing. It's hard to believe that I can have so much success and then get these buggers to ruin my excitement.
Lisa
- Replies
-
-
- November 8, 2011 at 9:25 pm
Lisa,
Indirectly, Ipilimumab keeps the T-cells actiavted and helps the T-Helper Cells activate the CD-8+ T-cells (CTLs) Cytotoxic T-Lymphocytes. The activated T-cells/ Macrophages cross the blood brain barrier and attack the Melanoma cells. They also reruite all the other immune cells to try to erradicate the tumor cells.
CTLA-4 Blockade With Ipilimumab Induces Significant Clinical Benefit in a Female With Melanoma Metastases to the CNS
F. Stephen Hodi, MD ; Darryl A. Oble, PhD ; Jan Drappatz, MD ; Elsa F. Velazquez, MD ; Nikhil Ramaiya, MD ; Naren Ramakrishna, MD, PhD ; Arthur L. Day, MD ; Andrea Kruse, BS ; Suzanne Mac Rae, BA, BS, MPH ; Axel Hoos, MD, PhD ; Martin Mihm, MD
Posted: 09/01/2008; Updated: 08/25/2008; Nat Clin Pract Oncol CME © 2008
http://www.nature.com/nrclinonc/journal/v5/n9/full/ncponc1183.html
Conclusion:
Yes, Indirectly Ipilimumab may/can cause bleeding in tumors. It is most likely the activated Macrophages doing the work.
This case describes pathological evidence of immune-mediated inflammation and edema with extensive tumor disruption and evidence of foci of necrosis within the CNS in response to ipilimumab therapy in a patient with advanced melanoma. Investigation of CTLA-4 blockade and other immune therapies to treat CNS metastases should be a focus of further clinical investigation.
I wish you all the best
Jimmy B
-
- November 8, 2011 at 9:25 pm
Lisa,
Indirectly, Ipilimumab keeps the T-cells actiavted and helps the T-Helper Cells activate the CD-8+ T-cells (CTLs) Cytotoxic T-Lymphocytes. The activated T-cells/ Macrophages cross the blood brain barrier and attack the Melanoma cells. They also reruite all the other immune cells to try to erradicate the tumor cells.
CTLA-4 Blockade With Ipilimumab Induces Significant Clinical Benefit in a Female With Melanoma Metastases to the CNS
F. Stephen Hodi, MD ; Darryl A. Oble, PhD ; Jan Drappatz, MD ; Elsa F. Velazquez, MD ; Nikhil Ramaiya, MD ; Naren Ramakrishna, MD, PhD ; Arthur L. Day, MD ; Andrea Kruse, BS ; Suzanne Mac Rae, BA, BS, MPH ; Axel Hoos, MD, PhD ; Martin Mihm, MD
Posted: 09/01/2008; Updated: 08/25/2008; Nat Clin Pract Oncol CME © 2008
http://www.nature.com/nrclinonc/journal/v5/n9/full/ncponc1183.html
Conclusion:
Yes, Indirectly Ipilimumab may/can cause bleeding in tumors. It is most likely the activated Macrophages doing the work.
This case describes pathological evidence of immune-mediated inflammation and edema with extensive tumor disruption and evidence of foci of necrosis within the CNS in response to ipilimumab therapy in a patient with advanced melanoma. Investigation of CTLA-4 blockade and other immune therapies to treat CNS metastases should be a focus of further clinical investigation.
I wish you all the best
Jimmy B
-
- November 8, 2011 at 9:25 pm
Lisa,
Indirectly, Ipilimumab keeps the T-cells actiavted and helps the T-Helper Cells activate the CD-8+ T-cells (CTLs) Cytotoxic T-Lymphocytes. The activated T-cells/ Macrophages cross the blood brain barrier and attack the Melanoma cells. They also reruite all the other immune cells to try to erradicate the tumor cells.
CTLA-4 Blockade With Ipilimumab Induces Significant Clinical Benefit in a Female With Melanoma Metastases to the CNS
F. Stephen Hodi, MD ; Darryl A. Oble, PhD ; Jan Drappatz, MD ; Elsa F. Velazquez, MD ; Nikhil Ramaiya, MD ; Naren Ramakrishna, MD, PhD ; Arthur L. Day, MD ; Andrea Kruse, BS ; Suzanne Mac Rae, BA, BS, MPH ; Axel Hoos, MD, PhD ; Martin Mihm, MD
Posted: 09/01/2008; Updated: 08/25/2008; Nat Clin Pract Oncol CME © 2008
http://www.nature.com/nrclinonc/journal/v5/n9/full/ncponc1183.html
Conclusion:
Yes, Indirectly Ipilimumab may/can cause bleeding in tumors. It is most likely the activated Macrophages doing the work.
This case describes pathological evidence of immune-mediated inflammation and edema with extensive tumor disruption and evidence of foci of necrosis within the CNS in response to ipilimumab therapy in a patient with advanced melanoma. Investigation of CTLA-4 blockade and other immune therapies to treat CNS metastases should be a focus of further clinical investigation.
I wish you all the best
Jimmy B
-
- You must be logged in to reply to this topic.